Dr. David King-Stephens, MD

Dr. King-Stephens practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. King-Stephens' NPI, 1700973633, was assigned on October 10, 2006. Dr. King-Stephens graduated from Universidad La Salle School of Medicine in 1988. Dr. King-Stephens holds California license A67009.

Dr. King-Stephens' primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. King-Stephens' primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. King-Stephens practices. Vendor and product names are available with a free account.

Epilepsy is Dr. King-Stephens' primary specialty in the NPI Registry, under taxonomy code 2084E0001X. Dmand AI has Dr. King-Stephens' licenses on file in 3 states: California, Connecticut and Pennsylvania.

Dmand AI lists acute mini-stroke (TIA), epilepsy and seizures among the conditions Dr. King-Stephens treats.

CMS data shows 45 Medicare services from Dr. King-Stephens across 2 procedure codes in 2024, for 80 Medicare patients. Medicare paid $5,666 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 80 Medicare patients who saw Dr. King-Stephens in 2024. The largest group is under 65, with 29 patients. 74% of them have high cholesterol, and 70% have high blood pressure. 54% are also on Medicaid. Their average risk score is 1.93, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. King-Stephens' median patient age at 45, with 46% women.

In 2024, Dr. King-Stephens wrote 317 Medicare Part D claims for 78 patients. 87% of them were for generic drugs. CMS names the drug for 212 of them, across 7 drugs with 11 or more claims each, at $8,673 in total drug cost. In 2023, CMS named 928 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. King-Stephens for performance year 2024, reported as part of a group. Dr. King-Stephens accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. King-Stephens as offering telehealth.

Dmand AI links 19 papers to Dr. King-Stephens, published from 2015 to 2025. 2023 was the busiest year, with 4. The most frequent topics are Brain, Electrocorticography and Electroencephalography. Dr. King-Stephens has published most often in Nat Commun. Dr. King-Stephens' most frequent co-authors are Kenneth D. Laxer, MD, Peter B. Weber, MD and Jack J. Lin, MD.

Dmand AI links Dr. King-Stephens to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Seizures, Epilepsy and Neurologic Manifestations.

CMS Open Payments shows 1,989 general payments to Dr. King-Stephens from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. UCB, Inc. paid the most, $559,856. It also lists 5 research payments totaling $7,043 from 2017 to 2018.

Dr. King-Stephens graduated from Universidad La Salle School of Medicine in 1988. Dr. King-Stephens is a member of AAN, AES, Epilepsy Foundation of Northern California, Pacific Epilepsy Jobs Program and San Francisco Neurological Society.

Dr. King-Stephens is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.